LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Celldex (NASDAQ:CLDX) Therapeutics Inc on Thursday, setting a price target of $68, which is approximately 45.11% above the present share price of $46.86.
Slutsky expects Celldex Therapeutics Inc to post earnings per share (EPS) of -$0.42 for the third quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Celldex, with an average price target of $62.67.
The analysts price targets range from a high of $68 to a low of $54.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $685 thousand and a net profit of -$16.16 million. The company's market cap is $2.18 billion.
According to TipRanks.com, LifeSci Capital analyst Sam Slutsky is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -3.2% and a 27.69% success rate.
Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.